Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers
- PMID: 16845533
- DOI: 10.1007/s00401-006-0104-6
Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers
Abstract
Alpha-synuclein aggregation is thought to be a key event in the pathogenesis of synucleinopathies. Although different alpha-synuclein alterations and modifications have been proposed to be responsible for early aggregation steps, the mechanisms underlying these events remain unclarified. Alpha-synuclein is a small protein localized to synaptic terminals and its intrinsic structure has been claimed to be an important factor for self-oligomerization and self-aggregation. Alpha-synuclein expression studies in cell cultures have demonstrated that posttranslational modifications, such as phosphorylation, oxidation, and sumoylation, are primarily involved in alpha-synuclein aggregation. Furthermore, in the last few years accumulating evidence has pointed to alternative splicing as a crucial mechanism in the development of neurodegenerative disorders. At least three different alpha-synuclein isoforms have been described as products of alternative splicing. Two of these isoforms (alpha-synuclein 112 and alpha-synuclein 126) are shorter proteins with probably altered functions and aggregation propensity. The present review attempts to summarize the data so far available on alpha-synuclein structure, posttranslational modifications, and alternative splicing as possible enhancers of aggregation.
Comment in
-
Announcing the winner of the 2006 Kurt Jellinger Prize.Acta Neuropathol. 2006 Sep;112(3):235. doi: 10.1007/s00401-006-0125-1. Epub 2006 Aug 10. Acta Neuropathol. 2006. PMID: 16900340 No abstract available.
Similar articles
-
Protein aggregation mechanisms in synucleinopathies: commonalities and differences.J Neuropathol Exp Neurol. 2007 Nov;66(11):965-74. doi: 10.1097/nen.0b013e3181587d64. J Neuropathol Exp Neurol. 2007. PMID: 17984679 Review.
-
Function of alternative splicing.Gene. 2005 Jan 3;344:1-20. doi: 10.1016/j.gene.2004.10.022. Epub 2004 Dec 10. Gene. 2005. PMID: 15656968 Review.
-
Alpha-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy.Biochem Soc Trans. 2005 Nov;33(Pt 5):1106-10. doi: 10.1042/BST20051106. Biochem Soc Trans. 2005. PMID: 16246056 Review.
-
α-Synuclein posttranslational modification and alternative splicing as a trigger for neurodegeneration.Mol Neurobiol. 2013 Apr;47(2):509-24. doi: 10.1007/s12035-012-8330-5. Epub 2012 Aug 25. Mol Neurobiol. 2013. PMID: 22923347 Review.
-
Cleavage of normal and pathological forms of alpha-synuclein by neurosin in vitro.Neurosci Lett. 2008 May 2;436(1):52-6. doi: 10.1016/j.neulet.2008.02.057. Epub 2008 Mar 4. Neurosci Lett. 2008. PMID: 18358605
Cited by
-
Alpha-synuclein increases in rodent and human spinal cord injury and promotes inflammation and tissue loss.Sci Rep. 2021 Jun 3;11(1):11720. doi: 10.1038/s41598-021-91116-3. Sci Rep. 2021. PMID: 34083630 Free PMC article.
-
Genetic regulation of alpha-synuclein mRNA expression in various human brain tissues.PLoS One. 2009 Oct 16;4(10):e7480. doi: 10.1371/journal.pone.0007480. PLoS One. 2009. PMID: 19834617 Free PMC article.
-
Analysis of alpha-synuclein in malignant melanoma - development of a SRM quantification assay.PLoS One. 2014 Oct 21;9(10):e110804. doi: 10.1371/journal.pone.0110804. eCollection 2014. PLoS One. 2014. PMID: 25333933 Free PMC article.
-
The Oligomer Hypothesis in α-Synucleinopathy.Neurochem Res. 2017 Dec;42(12):3362-3371. doi: 10.1007/s11064-017-2382-x. Epub 2017 Aug 21. Neurochem Res. 2017. PMID: 28828740 Review.
-
Modelling the role of UCH-L1 on protein aggregation in age-related neurodegeneration.PLoS One. 2010 Oct 6;5(10):e13175. doi: 10.1371/journal.pone.0013175. PLoS One. 2010. PMID: 20949132 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources